In the highly competitive life science industry, the question of whether funding size determines success has become increasingly relevant. While large investments often garner attention, is the amount of funding always the key to breakthrough discoveries? In this blog, Head-hunter Katie Davis explores the impact of funding size on research, development, and commercialization in the life science industry. We’ll dive into whether bigger budgets truly lead to better outcomes, or if strategic resource allocation and visionary leadership play a more pivotal role in advancing scientific progress.
I was having a conversation recently about stability of companies in the industry and the funding landscape. I always thought that the bigger the funding round the better, however, following an insightful conversation with an individual recently, I now have a new perspective!
This individual saw, for example, a $30 million Series B funding round a much more positive sign than a $100 million Series B round. Their reasoning being, that it generally indicates the company doesn’t need a huge amount of money to move to the next stage in it’s life cycle. This got me thinking about the pro’s and con’s around the different size funding rounds…
Larger funding rounds
Advantages:
- Greater financial resources for growth and strategic initiatives e.g. hiring top talent, faster scale up, R&D, quicker commercialisation, taking on larger projects etc.
- Having a longer run way and potentially reducing the need for additional rounds
- It shows investor confidence
- It enables aggressive market expansion
Disadvantages:
- Increased dilution
- Higher expectations and pressure to grow quickly
- Risk of over-valuation which can make future funding rounds more challenging
- Potential of inefficiency in spending and allocation of resources
Smaller funding rounds
Advantages:
- Less dilution
- Greater focus and discipline with prioritizing key projects, efficient growth and avoiding wasteful spending
- Less pressure to grow aggressively
- Easier to raise future rounds
- Flexibility to pivot strategy
Disadvantages:
- Limited financial resources and shorter runway
- Slower growth and risk of competitor outpacing the business
- Smaller funding rounds might mean there may be need for additional funding
- Missed market opportunities from slower product development, delay market entry etc.
Key considerations when deciding between a larger or smaller series round:
- Capital needs to reach key milestones
- Ownership vs. growth – how much equity are you willing to give up in exchange for capital?
- Market timing – is the marketing moving quickly, requiring more aggressive growth and faster funding, or is it better to take a more conservative, long-term approach
- Operational discipline – do you have a solid plan for optimising a smaller raise?
- Future funding plans – how will the current raise will affect future funding rounds
If you’re a life science startup looking for talent, or you’d like to learn more about our recruitment services, submit your vacancy and a recruitment consultant that specialises in your field will be in touch shortly.
Alternatively, are you seeking advice on your next move? I’m here to help. Register with us today to schedule a confidential discussion about your career prospects.
